A Phase 3 Randomized, Open-label Study Of Op-1250 Monotherapy Vs Standard Of Care For The Treatment Of Er+, Her2- Advanced Or Metastatic Breast Cancer Following Endocrine And Cdk 4/6 Inhibitor Therapy

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Jennifer Segar
Sponsor
PPD Development, LLC
Unit
Cancer Center Division